PHILADELPHIA -- Most multi-food allergic children succeeded in longer term regular dietary consumption whether treated with oral immunotherapy (OIT) or omalizumab (Xolair) alone, results from stage 3 ...

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

In a recent trial, Sindher’s team found that the injectable medication omalizumab reduces the risk of allergic reactions. Omalizumab is now FDA-approved for children one year and older, either alone ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts collaborated on a new clinical practice guideline published in CHEST, according to a ...

ARS Pharmaceuticals, Inc. reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending.

A string of FDA approvals and late-stage clinical trials has expanded the toolkit for treating seasonal and environmental allergies, giving patients new ways to manage symptoms and, in some cases, ...

Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, according to a study ...

DBV Technologies (NASDAQ:DBVT) outlined its late-stage plans for VIASKIN Peanut and its broader epicutaneous immunotherapy ...

Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study. The idea began when Dr. Mitch Biermann, an ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The lawsuit alleges the imported ...

PHILADELPHIA, March 2, 2026 /PRNewswire/ — LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and ...